Portal de Periódicos da CAPES

Safety and efficacy of an escalating dose regimen of pegylated interferon alpha-2b in the treatment of haemodialysis patients with chronic hepatitis C

2009; Wiley; Volume: 17; Issue: 6 Linguagem: Inglês

10.1111/j.1365-2893.2009.01191.x

1365-2893

S. S. Tan, Muhammad Radzi Abu Hassan, Ammar Adel Abdullah, Boon Phoe Ooi, T. Korompis, M. I. Merican,

Liver Disease Diagnosis and Treatment

Journal of Viral HepatitisVolume 17, Issue 6 p. 410-418 Safety and efficacy of an escalating dose regimen of pegylated interferon alpha-2b in the treatment of haemodialysis patients with chronic hepatitis C S. S. Tan, S. S. Tan Selayang Hospital, Batu Caves, Selangor, MalaysiaSearch for more papers by this authorM. R. Abu Hassan, M. R. Abu Hassan Hospital Alor Star, Alor Star, MalaysiaSearch for more papers by this authorA. Abdullah, A. Abdullah Selayang Hospital, Batu Caves, Selangor, MalaysiaSearch for more papers by this authorB. P. Ooi, B. P. Ooi Hospital Alor Star, Alor Star, MalaysiaSearch for more papers by this authorT. Korompis, T. Korompis Schering-Plough, Malaysia/SingaporeSearch for more papers by this authorM. I. Merican, M. I. Merican Selayang Hospital, Batu Caves, Selangor, MalaysiaSearch for more papers by this author S. S. Tan, S. S. Tan Selayang Hospital, Batu Caves, Selangor, MalaysiaSearch for more papers by this authorM. R. Abu Hassan, M. R. Abu Hassan Hospital Alor Star, Alor Star, MalaysiaSearch for more papers by this authorA. Abdullah, A. Abdullah Selayang Hospital, Batu Caves, Selangor, MalaysiaSearch for more papers by this authorB. P. Ooi, B. P. Ooi Hospital Alor Star, Alor Star, MalaysiaSearch for more papers by this authorT. Korompis, T. Korompis Schering-Plough, Malaysia/SingaporeSearch for more papers by this authorM. I. Merican, M. I. Merican Selayang Hospital, Batu Caves, Selangor, MalaysiaSearch for more papers by this author First published: 11 May 2010 https://doi.org/10.1111/j.1365-2893.2009.01191.xCitations: 8 S. S. Tan, Selayang Hospital, Lebuhraya Selayang-Kepong, Batu Caves, Selangor, Malaysia 68100. E-mail: tanss@selayanghospital.gov.my These data were presented in part at the 58th Annual Meeting of the American Association for the Study of Liver Diseases, November 2–6, 2007, Boston, MA, USA. Clinical trial registryThis clinical trial was begun in 2005, before the inception of the National Medical Research Register, and, therefore, was not registered at that time. The study has since been registered retrospectively with the National Medical Research Register (http://www.nmrrr.gov.my), protocol number P04418. Sources of supportSupport for this study was provided by The Malaysian Ministry of Health and Schering-Plough. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract Summary. Chronic hepatitis C is associated with increased morbidity and mortality in persons undergoing haemodialysis. This single-arm, open-label clinical trial investigated the safety and efficacy of an escalating dosage regimen of pegylated interferon (PEG-IFN) alpha-2b in this patient population. Patients with chronic hepatitis C who were undergoing haemodialysis began treatment with PEG-IFN alpha-2b at a dose of 0.5 μg/kg/week, which was increased every 4 weeks to a maximum of 1 μg/kg/week. Treatment duration was 24 weeks for patients with genotype (G) 2 or 3 infection and 48 weeks for patients with G1 infection. The primary end point was sustained virological response (SVR). Of 46 patients screened, 34 (G1: 70.6%; G3: 29.4%) were treated and 23 (67.6%) completed treatment. Overall, 85.3% of patients experienced early virological response, 52.9% experienced end-of-treatment response, and 50% attained SVR, with a trend toward higher SVR rates in G3 compared with G1 patients (80%vs 37.5%; P = 0.06). Anaemia was the main reason for discontinuation of treatment. Patients with chronic hepatitis C who are undergoing haemodialysis can be successfully treated with an escalating dosage regimen of PEG-IFN alpha-2b monotherapy. G3-infected patients can attain high rates of SVR with only 24 weeks of therapy. Citing Literature Volume17, Issue6June 2010Pages 410-418 RelatedInformation